Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 2 hours ago
Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
about 2 hours ago
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron...
Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief
about 3 hours ago
After decades of developing vaccines to shield babies and adults from Streptococcus...
Clinical trial flaws ‘being scaled, not solved’ by AI: report
about 21 hours ago
Clinical trial data company Phesi’s new analysis found that fewer than one...
Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
about 21 hours ago
Chinese companies now represent 50% of global out-licensing deals, with U.S. companies...
Incyte inks deal with Edison Scientific to train AI through drug discovery
about 21 hours ago
Incyte and Edison Scientific have signed a collaboration to employ Edison’s AI...
Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
about 22 hours ago
Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for...
Lauxera Capital Partners raises a hefty €520M for health, medtech companies
1 day ago
Lauxera Capital Partners has nearly doubled the size of its first funding...
Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial
1 day ago
Finnish biotech Herantis Pharma is teaming up with Swiss medtech Indivi to...
Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
1 day ago
Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve...
Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
1 day ago
Sanofi and Wave Life Sciences are using their time at the annual...
Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
2 days ago
Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss...
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
2 days ago
BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble...